American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 608-615 , April 2010

Risk Factors for Radiation Maculopathy after Ophthalmic Plaque Radiation for Choroidal Melanoma

  • Paul T. Finger

      Affiliations

    • The New York Eye Cancer Center, New York, New York
    • The New York Eye and Ear Infirmary, New York, New York
    • Corresponding Author InformationInquiries to Paul T. Finger, MD, The New York Eye Cancer Center, 115 East 61 Street, Suite 5B, New York, NY 10065
    • ,
  • Kimberly J. Chin

      Affiliations

    • The New York Eye Cancer Center, New York, New York
    • ,
  • Guo-Pei Yu

      Affiliations

    • The New York Eye and Ear Infirmary, New York, New York
    • ,
  • Palladium-103 for Choroidal Melanoma Study Group

,Accepted 1 November 2009.

References 

  1. Purdy J. Principles of radiologic physics, dosimetry and treatment planning. In:  Perez CABL editors. Principles and Practice of Radiation Oncology. 3rd ed.. Philadelphia: Lippincott-Raven; 1997;p. 243–279
  2. Purdy JA. Advances in three-dimensional treatment planning and conformal dose delivery. Semin Oncol. 1997;24:655–671
  3. Hall EJ. Radiation dose-rate: a factor of importance in radiobiology and radiotherapy. Br J Radiol. 1972;45:81–97
  4. Hall EJ. Weiss lecture (The dose-rate factor in radiation biology). Int J Radiat Biol. 1991;59:595–610
  5. Brady LW, Simpson LD, Day JL, Tapley ND. Clinical applications of electron beam therapy. In:  Perez CABL editors. Principles and Practice of Radiation Oncology. 3rd edition. Philadelphia: Lippincott-Raven; 1997;p. 321–332
  6. Finger PT. Radiation therapy for orbital tumors: concepts, current use and radiation side-effects. Surv Ophthalmol. 2009;54:545–568
  7. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42:215–232
  8. Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: the reusable “seed-guide” insert. Med Phys. 2005;32:2706–2716
  9. Merriam GR. A clinical study of radiation cataracts. Trans Am Ophthalmol Soc. 1956;54:611–653
  10. Lommatzsch PK. Possibilities and limitations of eye-preserving procedures in malignant melanoma of the uvea. Klin Monatsbl Augenheilkd. 1981;179:393–398
  11. Merriam GR, Focht EF. A clinical study of radiation cataracts and the relationship to dose. Am J Roentgenol Radium Ther Nucl Med. 1957;77:759–785
  12. Astrahan MA, Luxton G, Jozsef G, et al. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1990;18:679–687
  13. Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT. Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology. 1992;99:767–773discussion 774
  14. Finger PT, Berson A, Ng T, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys. 2002;54:1438–1445
  15. Boldt HC, Byrne SF, Gilson MM, et al. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no 29. Ophthalmology. 2008;115:1390–13971397e1–1397e2
  16. Malignant melanoma of the uvea. In:  Edge SEBD,  Carducci MA,  Compton CA editor. AJCC Cancer Staging Manual. 7th ed.. New York: Springer; 2009;p. 547–559
  17. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No 3. Control Clin Trials. 1993;14:362–391
  18. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89:730–738
  19. Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol. 1987;105:763–764
  20. Ray SK, Bhatnagar R, Hartsell WF, Desai GR. Review of eye plaque dosimetry based on AAPM Task Group 43 recommendations (American Association of Physicists in Medicine). Int J Radiat Oncol Biol Phys. 1998;41:701–706
  21. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56:544–555
  22. Beyer D, Nath R, Butler W, et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy (The clinical research committee of the American Brachytherapy Society). Int J Radiat Oncol Biol Phys. 2000;47:273–275
  23. Vikram B. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for palladium-103 brachytherapy: in regard to Beyer et al. IJROBP 2000;47:273-275. Int J Radiat Oncol Biol Phys. 2001;49:898–899author reply 899
  24. Finger PT, Romero JM, Rosen RB, Iezzi R, Emery R, Berson A. Three-dimensional ultrasonography of choroidal melanoma: localization of radioactive eye plaques. Arch Ophthalmol. 1998;116:305–312
  25. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84:1068–1070
  26. Finger PT, Chin KJ, Duval G. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology. 2009;116:790–796
  27. Finger PT. Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol. 2007;143:335–338
  28. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008;70:974–977
  29. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol. 2007;125:751–756

PII: S0002-9394(09)00809-5

doi: 10.1016/j.ajo.2009.11.006

American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 608-615 , April 2010

Article Tools

* Image Usage & Resolution